AAArghavan Azizpour

Arghavan Azizpour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arghavan Azizpour has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enhancing Dermatology Residents' Self‐Assessment Accuracy Through Training: An Interventional Study Using the Mini‐CEX

    by Arghavan Azizpour, Mohammad Jalili, Sara Mortaz‐Hejri, Maryam Nasimi, Vahideh Lajevardi, Maryam Ghiasi, Hanie Babaie

    Background: Self‐assessment is a key component of the formation and maintenance of clinical skills as well as a powerful type of formative assessment. The purpose of this study was to determine whether the mini–clinical evaluation exercise (mini‐CEX) improved the accuracy of dermatology residents' self‐assessments and their overall clinical performance. Methods: Fifty‐eight first‐ to fourth‐year dermatology residents participated in this study in the outpatient clinic and during inpatient visits from 2021 to 2022. At the beginning of the study, each resident was assessed by two faculty members at the same time but independently and also filled out a self‐evaluation test using the mini‐CEX examination. After the intervention and feedback on the result of the assessment, the participants were reassessed. Findings: After feedback and self‐assessment training, the mean scores that the evaluators gave to the residents improved significantly in interview skills, examination and the mean score across all assessed domains (all p < 0.05). The score of self‐assessment after the intervention had a significant increase in all seven categories of the mini‐CEX test (all p < 0.05). Following the intervention, there was a greater correlation between the ratings of professors and residents, suggesting improved alignment in performance evaluation. Conclusion: Training in self‐assessment and providing feedback appear to significantly enhance dermatology residents' ability to assess their own performance. These improvements not only reflect skill acquisition but also show the importance of incorporating structured self‐evaluation into residency programmes to promote clinical insight, lifelong learning and professional development across diverse medical specialties.

  • Open Access

    Probiotics in Psoriasis Management: A Randomized Trial on Disease Severity, Satisfaction, and Quality of Life

    by Fatemeh Kheirkhah, Hanie Babaie, Vahide Lajevardi, Soraiya Ebrahimpour-Koujan, Arghavan Azizpour

    Background: Psoriasis is a chronic systemic disease with an inflammatory process and systemic involvement that affects the quality of life. Recent research indicates that gut microbiota dysbiosis is common in psoriasis cases, and probiotics have been considered as a potential adjunct therapy; however, the current evidence is limited. The aim of this study was to assess the effects of probiotic supplementation on the severity of psoriasis, treatment satisfaction, and quality of life of patients. Methods: Forty‐four psoriasis patients between 18 and 70 years old were enrolled in this double‐blind, randomized, placebocontrolled trial. They received either topical corticosteroids with a probiotic supplement containing multiple bacterial strains or topical corticosteroids with a placebo for 12 weeks. At the end of the study, changes in the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), along with Treatment Satisfaction Questionnaire for Medication (TSQM), and adverse events were assessed. Results: Probiotic supplementation resulted in a greater reduction in PASI scores compared to the control group (46% vs. 15%, p = 0.002). At Week 12, the mean DLQI score was significantly lower in the probiotic group (4.364 ± 5.010) as compared to the control group (8.773 ± 6.015, p < 0.001), with 31.8% of probiotic users reporting no impact on quality of life (DLQI score 0‐1) versus 0% in controls. The patient satisfaction with treatment was significantly higher in the probiotic group. No adverse effects were reported. Conclusion: Probiotics can be recommended as a safe and effective adjunct therapy for psoriasis. They can enhance clinical outcomes, quality of life, and patient satisfaction. Further, larger trials are needed. Trial Registration: Iranian Registry of Clinical Trials: IRCT20130108012065N3


  • Open Access

    Basal cell carcinoma and squamous cell carcinoma: Comparison of high‐frequency ultrasound and pathology

    by Sepideh Keshavarz Valian, Faezeh Khorasanizadeh, Kambiz Kamyab, Sadra Nourazar, Sahar Montazeri, Arghavan Azizpour

    Background: Skin neoplasms, particularly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are prevalent forms of skin malignancies. To enhance accurate diagnosis, non‐invasive techniques including high‐frequency ultrasound (HFUS) are crucial. HFUS offers deeper penetration compared to reflectance confocal microscopy (RCM), and optical coherence tomography (OCT), making it valuable for examining skin structures. The aim of this study was to investigate and diagnose localized manifestation of BCC and SCC with HFUS and compare it with pathology results in patients referred to Razi Hospital, Tehran, Iran. Method and materials: This study included patients diagnosed with BCC and SCC, with clinical and pathological confirmation, attending the oncology clinic of Razi Hospital, Tehran, Iran, from 2022 to 2023. Exclusion criteria comprised metastatic and recurrent cases, patients who underwent treatment or surgery, and tumors located in anatomically challenging areas. HFUS with a 20 MHz probe and Doppler ultrasound were employed to examine the skin. Tumors were subsequently excised, fixed in formalin, and sent for pathological assessment. Ultrasound findings were compared with pathology results. Results: The study assessed 40 patients, with half diagnosed with SCC and the other half with BCC. The majority of SCC patients were male (80%), while BCC patients were relatively evenly divided between males (65%) and females (35%). The mean age was 59.15 ± 11.9 years for SCC and 63.4 ± 8.9 years for BCC. Cheeks (20%) and lips (35%) were the most common sampling sites for BCC and SCC, respectively. The correlation coefficients for tumor size and depth between ultrasound and pathology were 0.981 and 0.912, respectively, indicating a high level of agreement between the two methods. Conclusion: In BCC patients, there was complete agreement between sonographic loco‐regional extension and pathology findings. However, some discordance (30%) was observed in SCC cases. The study demonstrated a strong correlation between ultrasound and pathology in accurately detecting the depth and extent of the tumor. However, due to the inclusion of only patients with positive pathology, it is not appropriate to evaluate the diagnostic test values and compare them with pathology results. Therefore, it is highly recommended to carry out additional studies with larger sample sizes to further validate these findings.


  • Open Access

    Vellus hair removal with 1064‐nm neodymium: Yttrium–aluminum–garnet laser: A prospective study

    by Arghavan Azizpour, Pedram Nourmohammadpour, Maryam Nassimi, Roya Nemati, Zahra Sheikh, Zeinab Aryanian, Parvaneh Hatami

  • Open Access

    Investigating the impact of added Profhilo mesogel to subcision versus subcision monotherapy in treating acne scars; a single‐blinded, split‐face randomized trial

    by Mani Dastgheib, Sama Heidari, Arghavan Azizipour, Mohammadreza Kavyani, Vahide Lajevardi, Amir Hooshang Ehsani, Amir Teimourpour, Maryam Daneshpazhooh, Mansour Nassiri Kashani, Kamran Balighi

    Background: Acne scar is an inflammatory condition, which commonly occurs in patients with acne vulgaris, especially in adults. Mesogels have been reported effective in improving atrophic acne scars.Aims: We investigated the efficacy of adding Profhilo (a hyaluronic acid‐based filler) to subcision as a new treatment method.Methods: Twelve patients aged 18–45 years with atrophic acne scars on both sides of the face participated in this single‐blinded, split‐face, randomized controlled trial. Each side of the face was randomly assigned to one of the treatment methods, including subcision alone and subcision + Profhilo. Patients in the Profhilo arm received mesogel (1 cc) in addition to the subcision procedure. Both methods were carried out two times at 1‐month intervals. Assessments were done based on the sonographic depth of scars, and two blinded observers examined photographs at baseline and 3 months after the final session and the results were reported based on an exclusively made formula as the total score. The Global Improvement Scale and Visual Analogue Scale (VAS) (for patient satisfaction) were also used.Results: The VAS score of patient satisfaction was statistically significant in the Profhilo arm, with a mean improvement of 528.08 and 219.06 in the subcision arm (p = 0.02). No significant difference was seen in total acne scar reduction comparing the two methods (29.74 in the Profhilo arm and 22.27 in the subcision arm, p = 0.56). Sonographic depth reduction was also non‐significant, with a mean of 29.21 in the Profhilo arm and 28.53 in the subcision arm (p = 0.4). The mean global improvement was reported as four in both arms, and no statistical significance was observed (p = 0.89). The best response to treatment belonged to the rolling subtype in both methods (p = 0.029 for the Profhilo arm and p = 0.001 for the subcision arm).Conclusion: Despite no significant difference between the methods, Profhilo is more effective due to a higher satisfaction rate and better physiologic effects.


  • Open Access

    Combination therapy for management of pemphigus patients with unexpected therapeutic response to rituximab: A report of five cases

    by Zeinab Aryanian, Insha Zainab Riyaz, Kamran Balighi, Ali Ahmadzade, Hamid Reza Mahmoudi, Arghavan Azizpour, Parvaneh Hatami

    Key Clinical Message: The immunosuppressant agents should be considered earlier in the course of treatment with rituximab, possibly after the unfavorable response at first cycle of treatment, especially in male patients and those with high BMI. Rituximab (RTX) has recently been proposed as an alternative first‐line therapy for pemphigus patients. However, there are some rare reports of worsening of pemphigus following RTX therapy in the literature. This study aimed to evaluate the efficacy and safety of using a combination treatment of mycophenolate mofetil or dapsone and methotrexate in case of nonresponse, exacerbation or development of allergic reactions following rituximab therapy in pemphigus patients. In this case series, archive files of pemphigus patient in a tertiary care hospital from 2016 to 2021 who were treated with rituximab were reviewed and those with failure in treatment process including nonresponsiveness, exacerbation or development of allergic reactions to rituximab were identified and assessed. The study includes five patients out of 1245 RTX‐treated patients, who did not respond to RTX (one patient) or experienced an exacerbation of disease (two patients) or development of allergic reactions (two patients). Male patients with high BMI (BMI > 25) whose response to rituximab was not good at first cycle and happened to receive rituximab later in the course of disease, had highest number of relapses and benefited the most from this combination immunosuppressive treatment as an alternative for repeating rituximab cycles. The lower risk of relapse and a better chance of remission might indicate the efficacy of adjuvant immunosuppressant therapy in patients with no‐response, exacerbation, or allergic reaction to rituximab. These therapeutic effects were better observed in patients who received lower doses of rituximab which could suggest that the immunosuppressant agents should be considered earlier in the course of the disease, possibly after the first failed trial of rituximab therapy.


  • Open Access

    Coexistence of Pemphigus Vulgaris and Lichen Planus following COVID-19 Vaccination

    by Zeinab Aryanian, Kamran Balighi, Arghavan Azizpour, Kambiz Kamyab Hesari, Parvaneh Hatami

    SARS-CoV-2 vaccines were approved without long-term monitoring due to emergent situation and might have several side effects. Herein, we describe the first case with development of both LP and PV following COVID-19 vaccination. Immunological alteration due to COVID-19 vaccination and its potential role in triggering autoimmune disorders were also dealt with.


  • Clinical efficacy of mychophenolate mofetil in treating lichen planopilaris

    by Arghavan Azizpour, Parvaneh Hatami, Vahideh Lajevardi, Mehran Mohammadi, Zeinab Aryanian, Nessa Aghazadeh Mohandesi

    Lichen planopilaris (LPP) is a chronic inflammatory disorder of hair without a proven effective and safe treatment. To objectively assess the clinical efficacy of mycophenolate mofetil (MMF) in patients suffering from LPP, a retrospective cohort study was conducted on 52 patients who treated with MMF (2 g/day) at least for 6 months. LPP activity index (LPPAI) before and after treatment was calculated and compared. Most of the patients were female and belonged to the age group of 50-60 years. All of the disease activity indices were significantly improved after 6 months of therapy (p < 0.001). The majority of patients had LPPAI 4-6 and 0-2, before and after treatment, respectively. After 6 months of treatment, half of patients showed a disease activity decrease (LPPAI reduced >25% compared to the baseline value). Systemic MMF is an effective and relatively safe treatment modality for patients with LPP and could lead to significant reduction in disease activity regarding both subjective and objective indices.


  • Overestimation of subclinical atherosclerosis in psoriasis

    by Zeinab Aryanian, Azar Shirzadian, Raheleh Mehraeen, Morteza Ashrafian Amiri, Arghavan Azizpour, Azadeh Goodarzi, Parvaneh Hatami

    This study is one of a few that have been conducted to evaluate subclinical atherosclerosis in Iranian patients with psoriasis. Based on our findings, routine ultrasonography evaluation of all of patients with psoriasis does not seem to be reasonable or cost-effective.

  • Pemphigus patients with initial negative levels of anti‐desmoglein: A subtype with different profile?

    by Kamran Balighi, Nazanin Ashtar Nakhaei, Maryam Daneshpazhooh, Zeinab Aryanian, Saeed Aslani, Shadi Balighi, Arghavan Azizpour

    Background Pemphigus is a blistering autoimmune disease that is characterized by autoantibodies against desmoglins (Dsg), including anti-Dsg1 and anti-Dsg3. Despite the diagnosis of diseases, the anti-Dsg test by Enzyme-linked immunosorbent assay (ELISA) is negative in a small group of pemphigus patients. The aim of this study was to evaluate the clinical course, clinical symptoms, and response to treatment in pemphigus patients with negative levels of anti-Dsg1 and anti-Dsg3. Methods In this study, the data of pemphigus patients referred to Razi Hospital were retrospectively collected from the medical records from 2016 to 2020. Eight patients, whose initial anti-Dsg1/anti-Dsg3 was negative by the ELISA test, were enrolled and their clinical course, clinical signs, and response to treatment were evaluated. Results The mean age of the subjects (8 females) was 38.75±12.09. The most common phenotype of the subjects was pemphigus vulgaris (PV) with mucosal involvement. Additionally, the common site of blister inception was mouth of the patients. The mean prednisolone dose received by the patients at the initiation was 32.5±13.62 mg/day. According to Pemphigus Disease Area Index (PDAI), 6 patients had mild severity, wile 2 cases had moderate severity. Among the patients, 6 subjects received rituximab (RTX). Also, 5 patients experienced remission after 6.2±5.21 months. Conclusion PV is the most common phenotype of the disease and mucosal involvement is more common in patients with negative anti-Dsg-1/3 results. The severity of the lesions in most of the patients is mild at baseline and most patients seems to respond to RTX therapy and reach remission.